<DOC>
	<DOCNO>NCT03015220</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial investigate Safety efficacy oral semaglutide versus dulaglutide combination one OAD ( oral antidiabetic drug ) Japanese subject type 2 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Oral Semaglutide Versus Dulaglutide Both Combination With One OAD ( Oral Antidiabetic Drug ) Japanese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Japanese male female , age equal 20 year time signing informed consent Diagnosed type 2 diabetes mellitus least 60 day prior day screen HbA1c ( glycosylated haemoglobin ) 7.0 % 10.5 % ( 5391 mmol/mol ) ( inclusive ) OAD ( oral antidiabetic drug ) monotherapy stable daily dose least 60 day prior day screen one SU ( sulphonylurea ) glinide , TZD ( thiazolidinedione ) , αGI ( alphaglucosidase inhibitor ) SGLT2 ( sodiumglucose cotransporter2 ) inhibitor accord Japanese label Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method . Adequate contraceptive measure abstinence ( sex ) , diaphragm , condom ( partner ) , intrauterine device , sponge , spermicide oral contraceptive Any disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol Family personal history multiple endocrine neoplasia type 2 ( MEN 2 ) medullary thyroid carcinoma ( MTC ) History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Any follow : myocardial infarction , stroke hospitalisation unstable angina transient ischaemic attack ( TIA ) within past 180 day prior day screen randomisation Subjects presently classify New York Heart Association ( NYHA ) Class IV Planned coronary , carotid peripheral artery revascularisation know day screen Subjects alanine aminotransferase ( ALT ) 2.5 x upper normal limit ( UNL ) Renal impairment define estimate glomerular filtration rate ( eGFR ) 30 mL/min/1.73 m^2 per Chronic Kidney Disease Epidemiology Collaboration formula ( CKDEPI ) Treatment onceweekly glucagonlike peptide1 receptor agonist ( GLP1 RA ) weekly dipeptidyl peptidase4 ( DPP4 ) inhibitor period 90 day day screen For subject treat OAD TZD screening : Treatment TZD period 90 day day screen Treatment medication indication diabetes obesity addition background OAD medication ( SU , glinide , TZD , αGI SGLT2 inhibitor ) period 60 day day screen exception shortterm insulin treatment acute illness total least 14 day Proliferative retinopathy maculopathy require acute treatment . Verified fundus photography dilate fundoscopy perform within 90 day prior randomisation History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer situ carcinoma ) History diabetic ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>